EPO Analyses May Give J&J Fodder To Protect Procrit From Aranesp

Two recently released studies could help Johnson & Johnson in its efforts to ward off competition for its anemia therapy Procrit (epoetin) from Amgen's second-generation erythropoietin product Aranesp (darbepoetin)